Innovent Biologics / 信达生物

Innovent Biologics / 信达生物 appears in vol.117.生物医药的2025：抄底中国、研发焦虑和新王继位 through the episode’s discussion of [[DualPayloadADC|dual-payload ADCs]]. The source says related presentations from WuXi and Innovent showed this direction, where ADC design moves from one antibody plus one payload toward bispecific and dual-payload combinations.

The source treats Innovent as a signal of Chinese companies exploring harder ADC engineering, not as a settled proof that the format will become clinically or commercially dominant.

Connections

• Dual-Payload ADC and ADC Engineering Optimization - technical context.
• China Biotech Asset Repricing - broader Chinese biotech asset interest.
• Finite-Game Biotech Competition - mature-platform competition context.